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Recent advances in molecular genetics impact the
health care and outcome of patients with acute lym-
phoblastic leukemia (ALL). BCR-ABL, a common mo-
lecular defect in adult ALL, is a valuable tumor marker
whose detection influences prognosis and clinical
management decisions. Molecular methods such as
fluorescence in situ hybridization (FISH), reverse-
transcriptase polymerase chain reaction (rtPCR), and
real-time quantitative rtPCR can be used to detect the
chimeric BCR-ABL gene or its transcripts. These mo-
lecular assays improve our ability to measure residual
disease and to estimate risk of relapse. On the horizon
are gene expression profiles that will likely provide
additional information beyond what is obtainable
with current clinical and laboratory approaches. (J
Mol Diagn 2003, 5:63–72)
In 1960, Nowell and Hungerford1 reported the discovery
of what came to be known as the Philadelphia chromo-
some (Ph1) in association with chronic myelogenous leu-
kemia (CML). Their short report entitled “Minute chromo-
some in human chronic granulocytic leukemias” was the
first to demonstrate a leukemia-specific genetic abnor-
mality. In the ensuing decades, the pathology of the Ph1
has been studied and it is now known to represent an
abnormally shortened (derivative) chromosome 22 result-
ing from translocation with chromosome 9.2 The t(9;22) is
found in over 90% of CMLs, in a lesser proportion of
acute lymphoblastic leukemias (ALL) or biphenotypic
acute leukemias, and in rare cases of de novo acute
myelogenous leukemia (AML).
The break on chromosome 22q11.2 usually occurs in the
major breakpoint cluster region (M-BCR), in the minor
breakpoint cluster region (m-BCR), or rarely at other nearby
sites. The break on chromosome 9q34 involves the ABL
gene, named after Abelson murine leukemia virus where a
viral version of the ABL gene was first discovered. The
translocation brings the 5 end of the BCR gene into juxta-
position with the tyrosine kinase domain of the ABL gene to
produce a hybrid gene retaining tyrosine kinase activity.3
Depending on whether the M-BCR or m-bcr breakpoint is
involved in the translocation, transcription of the hybrid
gene results in chimeric mRNA encoding a 210 kd BCR-
ABL fusion protein or a 190 kd BCR-ABL fusion protein,
respectively. The reciprocal ABL-BCR translocation also
forms a chimeric gene that is capable of being transcribed,
but the pathological significance of this reciprocal chimeric
gene product is uncertain.
Laboratory Tests for t(9;22)
Conventional cytogenetics is the recommended test for
detecting t(9;22) in newly diagnosed leukemia patients.
Chromosome banding analysis has the advantage of
high specificity and an ability to detect alternate or addi-
tional cytogenetic defects that are valuable in diagnosis
and prognosis. However, cytogenetic analysis requires
viable marrow cells or more than 10% blasts in the pe-
ripheral blood to reliably culture the cells and visualize
metaphases. Occasionally fibrosis interferes with marrow
aspiration, yielding few analyzable metaphase cells. The
number of cells examined determines the sensitivity of
karyotyping. A typical examination of 20 cells carries a
sensitivity of one in 20, or 5%. Cryptic t(9;22) occurs in
about 5% of CML cases and also in a small proportion of
ALLs, resulting in false negative karyotypic interpretation
in metaphase spreads of cells that actually contain the
translocation at the molecular level.4
Fluorescence in Situ Hybridization
Fluorescence in situ hybridization (FISH) allows detection
of the BCR-ABL translocation in either metaphase or
interphase cells. Because interphase cells are suitable,
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FISH can be applied directly to blood leukocytes and
other non-dividing cells. Moreover, FISH detects cryptic
and complex BCR-ABL rearrangements such as three-
way translocations or breaks outside of the usual major
and minor cluster regions.4 Dual color FISH utilizes two
probes, one of which hybridizes to the 5 end of the BCR
region and the other to the 3 end of the ABL region.
Fluorescent microscopy is used to visualize these probes
which are typically labeled with red and green fluoro-
chromes to produce two red and two green spots repre-
senting the two copies of chromosomes 9 and 22 in
normal cells. In cells harboring a BCR-ABL translocation,
a red and green probe are juxtaposed to produce a
yellow fluorescent signal. Typically, 200 interphase or
metaphase nuclei are evaluated, yielding a sensitivity of
about 1 in 200, or 0.5%.
This classic dual-color single-fusion FISH (S-FISH) as-
say is highly accurate for analyzing metaphases, but is
hampered in its application to interphase cells by the
coincidental overlap of BCR and ABL signals in about 4%
of normal nuclei.5 Because it is prone to false positivity,
quantification below 10% is generally considered unreli-
able.6–9 To improve assay specificity, alternate strategies
were applied in the design of newer DNA probes. For
example, extra-signal FISH (ES-FISH) employs a larger
650-kb ASS-ABL probe (Vysis, Downer’s Grove, IL) which
targets an area spanning the ABL gene and the adjacent
arginino-succinate synthetase (ASS) gene. Since this
probe spans both sides of the ABL breakpoint cluster
regions, assay specificity is improved. In a validation
study conducted at our institution, 30 non-leukemic pa-
tients were assayed for the presence of the BCR-ABL
fusion using interphase ES-FISH. The background level
of fusion signals in marrow samples was less than or
equal to 5% with a confidence limit of 95%, indicating a
marginal improvement in assay specificity. ES-FISH is
also touted for its ability to distinguish M-BCR from m-
BCR based on the appearance of the spot pattern.10
(See Figure 1.)
Another strategy to improve assay specificity is dual-
fusion FISH (D-FISH). This involves applying probes that
span the common breakpoint regions of both ABL and
BCR genes so that one may visualize both the BCR-ABL
and the ABL-BCR fusion signals. In a commercial version
of this system (Vysis, Downers Grove, IL) the large ASS-
ABL probe mentioned above is combined with a large
probe spanning a distance of about 1.5 mb on both sides
of the BCR gene, thus providing a second confirmation of
the translocation and reducing the rate of false positives
to less than 0.5%.4,11–13 In addition, D-FISH, like S-FISH
and ES-FISH, can detect cryptic and complex BCR-ABL
translocations that are missed or undecipherable by con-
ventional cytogenetics.4
Southern Blot Analysis
Southern blot analysis reliably identifies BCR gene rear-
rangement using probes targeting either the M-bcr or
m-bcr breakpoint. While this is quite helpful in confirming
the BCR defect associated with CML or ALL, the South-
ern blot method suffers from high cost and slow turn-
around time. In addition, the assay is not sensitive for
detecting minimal residual disease since tumor levels
below about 5% are not detectable.
Amplification Technology
Reverse transcriptase polymerase chain reaction (rtPCR)
is the most sensitive method described to date for de-
tecting BCR-ABL. Instead of targeting chromosomal
DNA, the assay targets the more abundant chimeric RNA
transcripts produced from the fused genes. Chromo-
somal DNA is an impractical target not only because it is
less abundant than RNA but also because the breakpoint
regions span such large segments of intronic DNA that
multiple PCR primer sets would be required to detect
every possible translocation. On the other hand, the chi-
meric RNA is remarkably homogeneous from case to
case, thus allowing reliable detection of nearly all dis-
ease-associated translocations (Figure 2).
Amplification assays are capable of detecting one af-
fected cell among 100,000 or so normal cells. The ex-
ceptional sensitivity of rtPCR makes it well suited for
assessing minimal residual disease following therapy. A
downside that has hampered its implementation in clini-
cal laboratories is the possibility of false positive results
due to contamination of a negative specimen by ampli-
cons produced from prior positive amplification reac-
tions.14 Recent technological improvements such as
Figure 1. FISH using the Vysis Extra Signal (ES) probe reveals a normal result
yielding two green chromosome 22 and two red chromosome 9 signals (A);
one green, one red, and one red-green fusion signal, representing a pattern
that could be artifact due to coincidental juxtaposition of red and green
signals, or it could represent BCR-ABL translocation with concomitant loss of
chromosome 9 material proximal to the breakpoint, or finally it could rep-
resent an insertion of bcr into the chromosome 9 long arm at the abl locus
(B); typical findings in CML (p210 breakpoint) yielding one green, one red,
one residual red, and one red-green fusion signal (C); and typical findings in
ALL (p190 breakpoint) yielding one green, one red, and two red-green
fusions (D).
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chemical destruction of wayward amplicons (eg, uracil-
N-glycosylase system), or real-time detection of products
to avoid amplicon manipulation, help minimize the pos-
sibility of amplicon contamination.
Another cause for concern is physiological positive
results that mimic tumor-associated positive results. Spu-
rious positive results for BCR-ABL rtPCR are identified in
blood samples from up to 75% of normal individuals.15,16
The majority of these normal individuals express only
minute amounts of BCR-ABL transcripts that were de-
tected by highly sensitive assays capable of detecting 1
in 100 million tumor cells. Typical clinical assays are a
thousand-fold less sensitive and very rarely yield positive
results in healthy individuals. Nevertheless, it is advisable
to repeat any positive test when looking for residual dis-
ease and to compare the size of the amplicons with those
known to be produced from the patient’s tumor. Newly
available quantitative rtPCR assays now make it possible
to assess trends in the BCR-ABL load over time. These
quantitative tests are further described in the section on
minimal residual disease.
False negative amplification results are also a concern,
particularly since RNA is the substrate for rtPCR assays,
and RNA is notoriously subject to degradation by ubiq-
uitous RNase enzymes. It is therefore advisable to stabi-
lize RNA immediately on sample collection and to use
appropriate control tests to confirm that amplifiable cDNA
is present in each patient specimen.
Gene Expression Profiles and Microarray
Analysis
Microarrays have been used to survey gene expression
in ALL samples. A major advantage of array technology is
the ability to evaluate expression of thousands of genes
simultaneously. In a typical analysis, RNA is extracted
from the patient sample and converted to labeled cRNA
or cDNA before being applied to an array of complemen-
tary probes. Yeoh et al17 reported using 12,600 probe
sets to study 327 diagnostic marrow samples from child-
hood ALL patients. They could distinguish BCR-ABL
cases from other forms of ALL, and they also identified
additional subsets of patients at high risk of relapse
based on their gene expression profiles. The findings are
promising and will be followed by more studies aimed at
defining a smaller panel of probe tests that is informative
for diagnosis, classification, prognosis, and predicting
response to therapy.
Prevalence of BCR-ABL in Acute Leukemia
The reported prevalence of the Ph1 in adult ALL is 20 to 23%
by conventional cytogenetic testing.18–20 More sensitive
rtPCR techniques reveal a prevalence of 27 to 30%.20–22 In
a study by Gleissner et al,23 rtPCR testing for BCR-ABL
failed or produced false negatives in 19 of 212 patients
(9%). This was due to insufficient material in 10 cases,
ambiguous results in Ph1-negative patients in six cases,
and false negative test results in three cases. Cytogenetic
analysis failed or was falsely negative in 48 patients (23%)
including 32 non-analyzable and 16 false negative test re-
sults. Despite the possibility of failure, chromosome band-
ing analysis remains the best first-line genetic test to assess
any new acute leukemia because it screens for t(9;22) as
well as for alternate or additional genetic defects. When
negative or inconclusive results are obtained by cytogenet-
ics, then FISH or rtPCR are recommended to determine
whether BCR-ABL is present.
In childhood ALLs, the incidence of BCR-ABL translo-
cation is much lower at only 2 to 4% depending on the
method used for identification.24–27 BCR-ABL transcripts
are also present in 31 to 35% of biphenotypic acute
leukemia in adults and children,22,28 in 6% of de novo
adult AML,22 and in 1% of childhood AML.29
Clinical and Immunological Correlates at
Initial Diagnosis
The majority of BCR-ABL positive adult and childhood ALLs
have a typical pre-B cell immunophenotype with co-expres-
sion of CD10 (CALLA). Indeed, when results from five dif-
ferent studies were combined, including 170 adults and
children, 94% of BCR-ABL positive ALL had a pre-B cell
immunophenotype.20,24,26,30,31 In a study by Gleissner et
al23 on 875 adult ALL patients, the prevalence of BCR-ABL
positivity among CD10-expressing adult pre-B ALL was
37% whereas in the CD10-negative cohort it was only 2%.
The incidence of BCR-ABL in T-cell leukemias varies
among studies from 0% to 5%.20,23,24,26,30,31
Coexpression of myeloid markers, as defined by CD13
or CD33 in at least 20% of blasts, is found in 27 to 29% of
BCR-ABL positive adult and childhood ALL.23,30,32 My-
eloid markers are more frequently seen in BCR-ABL pos-
itive than in BCR-ABL negative ALL.23,26 There was no
correlation between myeloid co-expression and p190
versus p210 breakpoint,20,30 nor was there a correlation
with WBC count, blast count, hemoglobin, or hemato-
crit.31 Some investigators suggest that myeloid antigen
Figure 2. Diagrammatic representation of the BCR and ABL genes and the
corresponding BCR-ABL fusion transcripts. Arrows designate three different
breakpoint cluster regions in the BCR gene. Breaks in the M-BCR are most
commonly associated with CML, the m-BCR with ALL, and the -BCR with
chronic neutrophilic leukemia. ABL breakpoints usually occur between ex-
ons 1a and 2, resulting in fusion transcripts containing the tyrosine kinase
domain of the ABL gene and variable portions of the BCR gene.
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expression has an adverse impact on survival in BCR-
ABL positive ALL patients while others do not.19,30,32
Studies comparing the presenting clinical features of
BCR-ABL positive versus negative ALL have also pro-
duced conflicting results. Some investigators found no
significant difference in age, presenting WBC count, per-
centage of blasts, splenomegaly, or hepatomega-
ly20,26,30 while others found that BCR-ABL positive chil-
dren24,25 and adults23 had higher WBC counts and older
age. Recently, Gleissner et al reported that hepato-
splenomegaly was more common in BCR-ABL negative
adult ALL patients.23
The Significance of p210 versus p190
Breakpoint
An advantage of rtPCR and of certain FISH assays is the
ability to differentiate p210 from p190 forms of BCR-ABL.
Nearly all CML patients have a p210 breakpoint, and they
retain this genotype if their disease progresses to blast
crisis. In contrast, the majority of de novo Ph1-positive
acute leukemias harbor a p190 breakpoint. Therefore,
patients whose acute leukemia harbors a p210 break-
point should be evaluated to distinguish de novo acute
leukemia from blast crisis of CML. This distinction can be
difficult or impossible unless the patient had a prior white
cell count or signs and symptoms of CML, or unless the
patient reverts to chronic phase after treatment.
Among children and adults with Ph1 positive ALL, ap-
proximately 75% have p190 and 25% have a p210 break-
point in the BCR locus.20,23,26,30 Approximately 3% of
adult ALL patients express both p210 and p190 fusion
transcripts.23 This is explained by alternative splicing
whereby M-BCR breaks produce both p210 and, at a
lower level, p190 transcripts.23,33 Most studies show no
correlation between the type of breakpoint and clinical
parameters or prognosis,20,26,30,34 while a few studies
showed patients with p210 transcripts were likely to be
older.23,35 Some investigators found a tendency for p210
positive patients to do better36–38 or worse23 than p190
patients. In Ph1-positive AML patients, the p210 break-
point is present in about half while the rest have a p190
breakpoint. AMLs harboring a p190 breakpoint usually
have a monocytic (FAB M4 or M5a) phenotype.18,39
As noted above, alternative splicing can result in p190
transcript production from template DNA having a p210
breakpoint, and therefore CML or ALL (M-BCR break-
point) patients may have low levels of p190 transcripts,
usually not comprising over 10% of the total BCR-ABL
mRNA.33,40–43 In one study, p210 transcripts were de-
tected in all CML patients in accelerated phase or blast
crisis, and coexisting p190 transcripts were found in
8%.42 None of these patients had p190 mRNA at the time
of initial diagnosis. The association of p190 detection with
relapse was reported by Serrano et al in a study of 55
CML patients who underwent marrow transplant.43 All 14
patients who relapsed had become p190 positive by the
time of cytogenetic relapse. In contrast, the 41 patients
who remained in remission consistently tested negative
for p190 but not necessarily for p210. Radich et al37
studied 36 ALL patients at multiple timepoints after mar-
row transplant. Among 23 patients with at least one pos-
itive rtPCR result, 8 had p210 alone, 10 had p190 alone,
and 5 had both types of BCR-ABL transcripts. The pa-
tients with p190 transcripts detectable after transplant
were more likely to relapse than were patients with p210
alone or with undetectable BCR-ABL. This could be be-
cause p190 protein has stronger tyrosine kinase activity
and is associated with a more aggressive leukemia in
animal model systems.
The Impact of BCR-ABL on Prognosis of ALL
While early reports showed a lower response to induction
chemotherapy in Ph1-positive patients,24 this has not
been the case with the use of modern therapies. In a
large study of 1322 children with ALL, nearly all Ph1-
positive (97%) and Ph1-negative (98%) patients achieved
complete remission after induction therapy.25 But those
who had Ph1-positive leukemias were more likely to re-
lapse. The estimated 4-year event-free survival was only
20% for Ph1-positive as compared with 76% for Ph1-
negative patients. The four-year overall survival was 56%
for Ph1-positive and 85% for Ph1-negative patients. The
poor prognosis in children with Ph1 positive ALL was
confirmed by Schrappe et al,30 where complete remis-
sion was achieved in 90% but the 4-year event-free sur-
vival was only 38%, and 4-year overall survival was 48%.
Analogous to the situation in childhood ALL, young
adults consistently have a worse prognosis when their
ALL harbors BCR-ABL translocation. Gleissner et al23
found that 68% of BCR-ABL positive adult ALL patients
achieved complete remission compared to 85% of BCR-
ABL negative patients, with a higher frequency of early
relapses in BCR-ABL positive patients. The median over-
all survival was 11 months for BCR-ABL-positive and 30
months for BCR-ABL-negative patients. The 3-year over-
all survival was 15% for BCR-ABL-positive and 47% for
BCR-ABL-negative patients. Kantarjian et al, using a hy-
per-CVAD regimen to treat adult ALL, confirmed that the
complete remission rate for Ph1-positive patients was not
different from that of the whole cohort (91%), but their
5-year survival was only 7% as compared to 39% for the
entire study population.19 The findings may not extend to
the elderly, however, based on work from Onciu et al44
showing that ALL patients over 59 years of age did not
display an association between Ph1 and poor prognosis.
The prognosis of biphenotypic acute leukemia (BAL) is
worse than either ALL or AML. In a study of 23 adult BAL
patients by Legrand et al, complete remission was
achieved by 48% as compared to 65% of adult AML and
81% of adult ALL patients.22 The median overall survival
was 7.5 months for BAL, 11 months for AML, and 12
months for ALL. Killick et al, 45 in a report of 25 adult and
pediatric BAL patients, found that prognosis was strongly
related to t(9;22) status and age less than 15 years. The
two-year overall survival for adults was 17% and for chil-
dren was 75%. There was no difference in survival be-
tween children with Ph1-negative BAL and those with
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Ph1-negative AML or ALL suggesting that the worse
prognosis in BAL may be related to BCR-ABL positivity.
Impact of BCR-ABL on Selecting Therapy
for ALL
Because of the high rate of relapse and low overall sur-
vival in BCR-ABL positive acute leukemia patients, de-
tection of this genetic abnormality is considered an indi-
cation for allogeneic BMT in first remission.27,46,47 In a
report of 30 children with Ph1-positive ALL, 29 achieved
complete remission.25 Fifteen of these patients under-
went allogeneic BMT (five were related, seven were un-
related, and three were unspecified); 10 of these trans-
plants occurred at the time of first complete remission.
After follow-up for a median of 39 months, there were 6
event-free survivors among these 10 patients and only 2
event-free survivors among the other 20 patients, under-
scoring the utility of BMT in first remission.
In another study involving 61 children with BCR-ABL
positive ALL, 28 underwent marrow transplant (23 were
related, 5 were unrelated).30 The four-year event-free
survival for the whole group was 38%, 61% for patients
who were transplanted, and 28% for patients who re-
ceived only chemotherapy. Unrelated donor transplanta-
tion was associated with lethal toxicity in four of five
patients. On the other hand, 15 of the 19 patients who
received matched-related marrow transplant remained in
first complete remission, and their four-year event-free
survival was 83%.
As further support for transplant of Ph1-positive ALL
during first remission, a study of 32 such children was
conducted.26 Thirty achieved complete remission, of
whom eight then received allogeneic marrow, three re-
ceived autologous marrow, and 19 received chemother-
apy alone. Subsequently, three of the latter patients re-
ceived allogeneic marrow and one received autologous
marrow. All patients relapsed except six of the eight
patients who received allogeneic marrow during first re-
mission. There were no long-term survivors among re-
lapsed patients despite treatments including allogeneic
transplant.
Two long-term prospective studies confirm that adult
ALL has a poor prognosis.48,49 The highest risk was in
patients who were over 35 years of age, Ph1-positive, had
leukocyte counts above 30  10(9)/L, had null ALL or
undifferentiated leukemia, or required longer than four
weeks to achieve complete remission. A few studies spe-
cifically addressed the role of allogeneic BMT in Ph1-
positive patients. Improved survival data were reported
by Forman et al50 in 10 such patients of whom six were
alive and well for a median of 19 months. Snyder et al51
showed that 23 Ph1-positive adult ALL patients who were
transplanted in first remission had improved disease-free
survival (65% at 3 years). Mitterbauer et al21 reported that
allogeneic transplant was more effective than chemother-
apy alone in reducing BCR-ABL levels and in achieving
long term remission. Among adults treated with stem cell
transplant in first remission for Ph1 ALL, Dombret et al38
showed that those who achieved negativity for BCR-ABL
before transplant had improved remission duration and
survival after transplant.
Gleevec Therapy for BCR-ABL Leukemias
Imatinib (Gleevec), which targets the ABL tyrosine kinase
hyperactivity of the BCR-ABL oncoprotein, has been
shown to be effective in the treatment of CML or CML in
myeloid or lymphoid blast crisis.52,53 Unfortunately,
Gleevec resistance sometimes develops after an initial
response. A study by Gorre et al54 showed that Gleevec
resistance in nine CML patients was associated with
reactivation of tyrosine kinase activity. In three patients,
there was BCR-ABL chimeric gene amplification, while
the other six patients acquired a point mutation in the
tyrosine kinase domain of BCR-ABL (Thr315Ile).
Gleevec is also temporarily effective in treatment of
BCR-ABL-positive ALL as shown in a recent report of 21
patients who had initially relapsed or failed to respond to
standard chemotherapy.55 With Gleevec therapy, 13 of
these patients were classified as good responders (12
achieved complete hematological remission and one
achieved partial remission with peripheral hematological
recovery). Marrow aspirates of 9 of the 21 patients (5
good responders and 4 resistant patients) were obtained
before and after therapy. Direct sequencing of cDNA
representing a 714 bp segment of ABL encoding the
ATP-binding site and the kinase activation loop showed
an acquired point mutation at position 1127 (Glu255Lys)
in 6 patients (4 good responders and 2 resistant pa-
tients). A seventh resistant patient acquired a point mu-
tation at nucleotide 1308 (Thr315Ile). Other reports have
confirmed the acquisition of point mutations in the ATP-
binding domain of BCR-ABL in ALL and CML patients
who became resistant to Gleevec.56 Screening for these
mutations may allow therapy to be altered before frank
relapse.
Minimal Residual Disease Detection
Detection of minimal residual disease is beneficial to
patients with ALL, and advances in laboratory technology
provide new and more powerful ways to detect low level
disease.57–59 Most investigators have applied one of
three approaches: 1) PCR amplification of rearranged
IgH or TCR genes using custom-designed tumor-specific
primers and probe; 2) multiparameter flow cytometry; or
3) Quantitative PCR of tumor-associated translocation
breakpoints. All three approaches have merit. Targeting
the IgH or TCR genes is feasible in nearly all cases of
ALL, but the development of customized IgH or TCR
probes is costly and labor-intensive. Flow cytometry is
quite helpful assuming that the leukemic clone has an
aberrant phenotype not prevalent in normal cells in the
sample.
Analysis of tumor-specific translocations is a promising
alternative for evaluating minimal residual disease in
those patients whose tumor harbors a translocation for
which a reliable laboratory assay is available.60,61 BCR-
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ABL is an appealing target considering that a significant
proportion of ALLs harbor the translocation (about 28% of
adult ALL; 3% of childhood ALL), and sensitive assays
are available for detecting it by rtPCR. Such amplification
assays are the most sensitive of all laboratory ap-
proaches, followed by flow cytometry, FISH, and cytoge-
netics, with associated detection thresholds of about 1 in
1 million, one in several thousand, one in several hun-
dred, and 1 in 20, respectively. (See Figure 3.)
Real-time quantitative rtPCR techniques are now avail-
able that permit precise measurement of chimeric tran-
scripts. Levels can be reported either in absolute terms or
relative to a housekeeping transcript. Recent studies us-
ing this technology to detect BCR-ABL transcripts have
shown good correlation with the results of cytogenetic
analysis, FISH, Southern blot analysis, and conventional
nested rtPCR.62–64 Various platforms such as the ABI
Prism 7700 (Applied Biosystems, Foster City, CA) or the
LightCycler (Roche Diagnostics, Indianapolis IN) were
able to reproducibly detect one positive cell from among
10,000 to 100,000 normal cells.62–70
Investigators have consistently demonstrated the prog-
nostic value of molecular analysis of BCR-ABL transcripts in
the management of ALL patients. After successful marrow
transplantation, ALL patients tend to become rtPCR nega-
tive within six weeks.71 Persistence of BCR-ABL transcripts
is associated with a high risk of relapse, while those who
remain rtPCR negative have a good prognosis.37,71–73 Dis-
ease-free survival is related to the rtPCR status after marrow
transplantation regardless of the presence of residual dis-
ease before transplantation.73,74
The predictive value of molecular follow-up has been
confirmed in a study by Radich et al37 of 36 adults and
children who were transplanted for Ph1-positive ALL. Pa-
tients in whom rtPCR was positive on one or more occa-
sions after transplant were more likely to relapse, and the
unadjusted relative risk of relapse for a positive test was
5.7. A positive p190 result was particularly indicative of a
high risk of relapse while p210 positivity was not. Indeed,
of 10 transplant patients who were rtPCR positive and
relapsed, 9 had p190 either alone (7 patients) or in con-
cert with p210 (2 patients). In a more recent study by
Radich et al, 72 the ABI Prism 7700 real-time rtPCR plat-
form was used to quantitate BCR-ABL in posttransplant
samples from 12 CML patients who relapsed and 73
patients who remained in remission. BCR-ABL levels
were a significant prognostic indicator in these divergent
outcome groups.
There is reasonably good correlation between BCR-
ABL rtPCR results from blood and marrow samples col-
lected at the same time. Lin et al reported complete
concordance in blood and marrow samples obtained on
23 occasions from CML patients following allogeneic
BMT or interferon therapy.75 Positive cases showed good
correlation in the number of BCR-ABL transcripts per
microgram of RNA (r  0.99). Radich et al found a 91%
correspondence in BCR-ABL rtPCR results between
blood and marrow samples obtained on 605 occasions
from CML patients who had undergone allogeneic
BMT.72 Evaluation of the occasional discordances
showed marrow alone was positive in 36 cases while
blood alone was positive in 18 cases. In an analogous
study of ALL patients, Radich et al37 reported a 74%
concordance in samples obtained on 31 occasions from
ALL patients who had undergone allogeneic BMT, with
the few discrepancies involving marrow-only positivity in
five cases and blood-only positivity in three cases. The
findings suggest that either blood or marrow samples
may be suitable for follow up of BCR-ABL associated
leukemias. Surprisingly, archival formalin-fixed paraffin or
acrylate-embedded marrow biopsies have recently been
shown to be suitable sample types for BCR-ABL rtPCR.76
It is theorized that minimal residual disease after mar-
row transplantation could be controlled with relatively
modest intervention. A recent report showed that residual
BCR-ABL transcripts in two ALL patients were rendered
undetectable following acute graft versus host disease.
Either donor lymphocyte infusion (DLI) or rapid reduction
of immunosuppression caused this graft versus host ef-
fect, and it was associated with lasting disease remis-
sion.77 Similarly, it has been shown that CML patients
who achieve complete remission after DLI have pro-
longed survival. In a study of 39 CML patients who
achieved cytogenetic remission with DLI, the overall
probability of survival was 87% at 1 year, 76% at 2 years,
and 73% at 3 years (median follow-up of 40 months after
DLI).78 The use of rtPCR positivity as the criterion for
relapse following allogeneic BMT and as the indication
for DLI has been investigated. Mughal et al presented
data on 20 CML patients in molecular relapse who were
treated with DLI.79 After a median follow-up of 42 months,
these patients were in continuous molecular remission.
Their actuarial probability of survival at 10 years after
BMT was 100% and their probability of relapse was 0%.
The actuarial probability of survival at 10 years for 63
control CML patients who had been continuously PCR
negative after allogeneic BMT was 97% (median fol-
low-up of 8.4 years after allogeneic BMT). The availability
of such effective measures for detecting and dealing with
minimal residual disease is promising.
Currently there are no definitive guidelines on when or
how frequently to monitor BCR-ABL for purposes of min-
imal residual disease detection in ALL patients. If we
Figure 3. Laboratory tests are capable of detecting tumor burden at different
levels. Up to a billion leukemic cells may remain in a patient who is in
hematological remission, underscoring the importance of using more sensi-
tive assays to detect and measure minimal residual disease. Theoretically,
rising levels permit early intervention so that the number of cell divisions is
minimized and the accompanying risk of secondary genetic events is like-
wise reduced.
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extrapolate from the extensive literature on monitoring
BCR-ABL in CML patients, we infer that the type of test
and frequency of its application depends on which ther-
apy is used and on its curative versus palliative inten-
tion.73 CML treated with hydroxyurea, busulfan, or other
conventional non-curative therapy relies on cytogenetics
to monitor residual disease and to detect markers of
progression, while more sensitive molecular tests such as
FISH are only marginally more informative, and rtPCR is
probably not needed at all.9 When interferon therapy is
used to treat CML, the European consortium recom-
mends that once the number of Ph1-positive cells has
fallen below 10% by karyotype then quantitative rtPCR
should be performed every 3 months.81 Interferon should
be continued until the BCR-ABL/ABL ratio is lower than
0.02%.82 After stem cell transplant, the European consor-
tium recommends quantitative rtPCR be done every 4
weeks for as long as BCR-ABL is detectable, then at
intervals of 3 months and, after 1 year of undetectable
levels, at up to 6-month intervals.81 If levels increase,
immediate retesting helps to confirm and direct interven-
tion. This group has defined molecular relapse as a 1 log
(10-fold) or greater increase in BCR-ABL determined by a
minimum of three consecutive quantitative rtPCR tests
regardless of the interval between these tests. Lin et al
defined molecular relapse as 50 transcripts per micro-
gram of RNA or increasing values on serial testing.83 A
more recent report from the same institution by Olavarria
et al suggested the following criteria: A) the BCR-ABL/
ABL ratio is 0.02% on three consecutive occasions over
1 month apart; or B) the ratio is 0.05% on two consec-
utive samples; or C) the transcript number is rising in
three consecutive samples, with at least two samples
having ratios above 0.02%.84
The National Comprehensive Cancer Network (NCCN)
recommends less frequent monitoring of residual disease in
CML.85 According to their recent practice guidelines, after
hematological remission is achieved following allogeneic
marrow transplant, cytogenetics and rtPCR should be done
every 6 months for the first 2 to 3 years and yearly thereaf-
ter.85 If karyotype is positive at any timepoint, the patient
should be treated for relapse with interferon or donor lym-
phocyte infusion (DLI). If rtPCR is positive but karyotype is
negative, the patient should be observed and retested ev-
ery 6 months for 2 years and then every 12 months. After
treatment of relapse, the guidelines recommend rtPCR test-
ing every 6 months for 2 years and yearly thereafter, with
cytogenetic testing at any rtPCR-positive timepoint. Several
clinical trials are underway to further determine the utility
and recommended frequency of laboratory monitoring of
CML, particularly now that Gleevec has been added to the
armamentarium. Of note, one mechanism of Gleevec resis-
tance is amplification of the BCR-ABL chimeric gene, lead-
ing to overexpression of the fusion transcript rather than the
anticipated decrease expected with successful therapy.54
Conclusion
Patients with pre-B ALL should be tested for BCR-ABL at
the time of diagnosis to identify those who have the
translocation and who therefore carry a worse prognosis
and are candidates for treatment with intensive induction
regimens and marrow transplantation. Transplantation
during first remission appears to benefit such patients.
Studies are underway to assess alternative treatment
programs such as Gleevec for their role in disease man-
agement.
Karyotype should be initially performed on all sus-
pected ALL patients. While karyotyping has the advan-
tage of being able to detect a large variety of genetic
alterations, it is also vulnerable to false negative results.
FISH and rtPCR are helpful for detecting occult t(9;22)
and for differentiating p190 and p210 breakpoints. Am-
plification strategies are quite sensitive and thus well
suited for follow-up to detect minimal residual disease.
One caveat, however, is that trends in BCR-ABL test
results rather than a value obtained at a single timepoint
should be taken into consideration before making clinical
management decisions. The recent advent of quantitative
BCR-ABL rtPCR testing permits precise measurement of
low levels of BCR-ABL that appear to reflect trends in
tumor burden.
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